

---

Patient [Name/ID Number]

---

Name of epcoritamab treating physician

---

Treating physician's phone number (during office hours)

---

Treating physician's emergency care phone number (after office hours)

---

Next of kin emergency contact information

---

Date of first dose of epcoritamab

---

Version 1.0 / UK-EPCOR-230048 / October 2023



## Tepkinly<sup>®</sup> ▼ (epcoritamab) Patient Card

**Please carry this card with you at all times. Show it to any healthcare professional who sees you and when you go to any hospital.**

Tell any healthcare professional who sees you that you are being treated with Tepkinly ▼ (epcoritamab).

If you get any side effects following your treatment with epcoritamab, please talk to your doctor or nurse.

Be careful while driving, cycling, or using heavy or potentially dangerous machines. If you have any of the symptoms described on this card, you should avoid these activities.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you get. See <https://yellowcard.mhra.gov.uk> for how to report side effects or via the free Yellow Card App from the Google Play or Apple App Store.

## Important Safety Information for Patients

Epcoritamab may cause side effects which can be serious. Read the patient information leaflet for more information.

**Call your doctor or get emergency help immediately if you have any of the following symptoms:**

- Fever (38°C or higher)
- Dizziness or light-headedness
- Chills
- Fast heartbeat
- Difficulty/trouble breathing
- Headache
- Difficulty speaking or writing
- Drowsiness
- Confusion/disorientation
- Muscle weakness
- Seizures
- Memory loss

## Important Safety Information for Healthcare Professionals

This patient is being treated with epcoritamab, a T-cell engaging bispecific antibody.

Following treatment with epcoritamab, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) may occur, which may be serious or fatal if not treated promptly. CRS may occur several hours or days after epcoritamab administration, usually after the first full dose in Cycle 1. ICANS may occur several days or weeks after epcoritamab administration.

**Contact the patient's treating physician immediately for further information (contact details overleaf).**

Consult the Summary of Product Characteristics for more information. An electronic version of the Patient Card can be accessed via [www.medicines.org.uk](http://www.medicines.org.uk)